Triptorelin
- Generic Name
- Triptorelin
- Brand Names
- Decapeptyl, Trelstar, Triptodur
- Drug Type
- Small Molecule
- Chemical Formula
- C64H82N18O13
- CAS Number
- 57773-63-4
- Unique Ingredient Identifier
- 9081Y98W2V
- Background
Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.
- Indication
Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
- Associated Therapies
- Controlled ovarian hyperstimulation therapy
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 2672
- Registration Number
- NCT00066703
- Locations
- 🇺🇸
Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸Memorial Hospital of South Bend, South Bend, Indiana, United States
🇺🇸Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
Premenopausal Endocrine Responsive Chemotherapy Trial
- Conditions
- Breast Cancer
- Interventions
- Drug: chemotherapyProcedure: oophorectomyProcedure: ovarian irradiation
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 29
- Registration Number
- NCT00066807
- Locations
- 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇨🇭Kantonsspital - St. Gallen, St. Gallen, Switzerland
🇮🇹Centro di Riferimento Oncologico - Aviano, Aviano, Italy
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
- Conditions
- Recurrent Breast CarcinomaStage IA Breast CancerStage IB Breast CancerStage IIIA Breast CancerEstrogen Receptor Positive Breast CancerProgesterone Receptor Positive TumorStage IIA Breast CancerStage IIB Breast Cancer
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Quality-of-Life AssessmentProcedure: OophorectomyRadiation: Radiation Therapy
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 3066
- Registration Number
- NCT00066690
- Locations
- 🇺🇸
Charlotte Hungerford Hospital Center for Cancer Care, Torrington, Connecticut, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Finley Hospital, Dubuque, Iowa, United States
Hormone Therapy in Treating Patients With Advanced Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-07-02
- Target Recruit Count
- 966
- Registration Number
- NCT00003026
- Locations
- 🇳🇱
St. Elisabeth Ziekenhuis, Tilburg, Netherlands
🇳🇱Academisch Ziekenhuis Groningen, Groningen, Netherlands
🇬🇧City General Hospital, Stoke-On-Trent, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.